BIO vs COLL · rev $2.58B vs P/E 17, rev $181.9M
BIO (BIO) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
BIO currently screens at market cap $0. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the BIO and COLL stock pages for the full models.
Not investment advice.